Neuphoria Therapeutics Inc. financial data

Symbol
NEUP on Nasdaq
Location
Burlington, MA
Fiscal year end
30 June
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 387% %
Debt-to-equity 47% %
Return On Equity -53% % 11%
Return On Assets -36% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,357,613 shares -100%
Common Stock, Shares, Outstanding 2,357,613 shares
Entity Public Float $5,213,998 USD -61%
Common Stock, Value, Issued $23 USD
Weighted Average Number of Shares Outstanding, Basic 2,246,066 shares 73%
Weighted Average Number of Shares Outstanding, Diluted 2,246,066 shares 73%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $15,000,000 USD
Research and Development Expense $10,889,843 USD 32%
General and Administrative Expense $7,973,658 USD 2.7%
Operating Income (Loss) $3,214,053 USD 80%
Nonoperating Income (Expense) $6,628,268 USD -233%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,842,321 USD 11%
Income Tax Expense (Benefit) $370,972 USD -101%
Net Income (Loss) Attributable to Parent $9,501,717 USD 12%
Earnings Per Share, Basic -4 USD/shares 79%
Earnings Per Share, Diluted -4 USD/shares 79%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,649,638 USD 69%
Accounts Receivable, after Allowance for Credit Loss, Current $1,758 USD -98%
Assets, Current $13,952,279 USD 66%
Property, Plant and Equipment, Net $2,573 USD 31%
Operating Lease, Right-of-Use Asset $75,219 USD -62%
Intangible Assets, Net (Excluding Goodwill) $4,639,108 USD -12%
Goodwill $8,674,734 USD -2.6%
Assets $27,343,913 USD 19%
Accounts Payable, Current $1,370,728 USD 3.4%
Liabilities, Current $5,124,276 USD 101%
Deferred Income Tax Liabilities, Net $460,320 USD -45%
Operating Lease, Liability, Noncurrent $19,322 USD
Other Liabilities, Noncurrent $3,647 USD
Liabilities $14,833,726 USD 154%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,795,845 USD -15%
Retained Earnings (Accumulated Deficit) $188,253,207 USD -5.3%
Stockholders' Equity Attributable to Parent $12,510,187 USD -27%
Liabilities and Equity $27,343,913 USD 19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,794,648 USD 14%
Net Cash Provided by (Used in) Financing Activities $3,253,615 USD
Common Stock, Shares Authorized 30,000,000 shares
Common Stock, Shares, Issued 2,357,613 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $560,488 USD 88%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,728,202 USD 68%
Deferred Tax Assets, Valuation Allowance $26,139,160 USD -5.6%
Deferred Tax Assets, Gross $26,956,776 USD -5%
Operating Lease, Liability $85,210 USD -61%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $9,838,980 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid $145,275 USD
Property, Plant and Equipment, Gross $47,716 USD -0.09%
Operating Lease, Liability, Current $85,210 USD -34%
Lessee, Operating Lease, Liability, to be Paid, Year Two $182,854 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $119,593 USD -38%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,457 USD -98%
Preferred Stock, Shares Authorized 3,000,000 shares
Additional Paid in Capital $203,559,216 USD 2.7%
Deferred Tax Assets, Net of Valuation Allowance $26,100,000 USD -5.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares